
GOSS Stock Forecast & Price Target
GOSS Analyst Ratings
Bulls say
Gossamer Bio Inc. has garnered positive sentiment from key opinion leaders (KOLs), particularly regarding its product PROSERA for pulmonary arterial hypertension (PAH), with expectations of significant treatment effects that could further enhance its market position. The recent Phase 2 TORREY data demonstrated consistent benefits across multiple endpoints, including reductions in pulmonary vascular resistance and pro-BNP levels, alongside encouraging safety profiles and durability in clinical outcomes. Increased investor interest following bullish commentary from KOLs at recent conferences highlights growing confidence in Gossamer Bio's therapeutic pipeline and potential for future growth.
Bears say
Gossamer Bio Inc. is facing a challenging outlook, primarily due to the market's continued mispricing of the odds associated with its lead product, seralutinib, despite recent increases in stock value. The mispricing reflects a broader skepticism regarding the potential success of its clinical pipeline in the competitive biopharmaceutical landscape. This uncertainty regarding the approval and commercial viability of its therapeutic candidates, including those for pulmonary arterial hypertension and inflammatory bowel diseases, contributes to a negative sentiment surrounding the company's financial prospects.
This aggregate rating is based on analysts' research of Gossamer Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
GOSS Analyst Forecast & Price Prediction
Start investing in GOSS
Order type
Buy in
Order amount
Est. shares
0 shares